{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:10:22Z","timestamp":1791090622327,"version":"4.1.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12,1]]},"DOI":"10.1215\/15228517-2009-010","type":"journal-article","created":{"date-parts":[[2009,3,17]],"date-time":"2009-03-17T22:24:21Z","timestamp":1237328661000},"page":"853-860","source":"Crossref","is-referenced-by-count":136,"title":["Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)"],"prefix":"10.1093","volume":"11","author":[{"given":"Patrick Y.","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.K. Alfred","family":"Yung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen R.","family":"Lamborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Norden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy F.","family":"Cloughesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Abrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Ian","family":"Robins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"DeAngelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minesh","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Di Tomaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Drappatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Kesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith L.","family":"Ligon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Aldape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Stiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrill J.","family":"Egorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Prados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,1]]},"reference":[{"key":"key\n\t\t\t\t20171013170945_REF1","doi-asserted-by":"crossref","unstructured":"Bondy M, Ligon BL. Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol. 1996;29:197-205.","DOI":"10.1007\/BF00165649"},{"key":"key\n\t\t\t\t20171013170945_REF2","unstructured":"DeMonte F, Marmor E, Al-Mefty O. Meningiomas. In: Kaye AH, Laws ER Jr, eds. Brain Tumors. London: Churchill Livingstone; 2001:719-750."},{"key":"key\n\t\t\t\t20171013170945_REF3","unstructured":"Meningeal tumors. In: Kleihues P, Cavenee WK, eds. WHO Classification of Tumors of the Nervous System. Lyon, France: International Agency for Research on Cancer; 2000:175-196."},{"key":"key\n\t\t\t\t20171013170945_REF4","doi-asserted-by":"crossref","unstructured":"Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg. 1985;62:18-24.","DOI":"10.3171\/jns.1985.62.1.0018"},{"key":"key\n\t\t\t\t20171013170945_REF5","doi-asserted-by":"crossref","unstructured":"Kondziolka D, Levy EI, Niranjan A, Flickinger JC, Lunsford LD. Long-term outcomes after meningioma radiosurgery: physician and patient perspectives. J Neurosurg. 1999;91:44-50.","DOI":"10.3171\/jns.1999.91.1.0044"},{"key":"key\n\t\t\t\t20171013170945_REF6","doi-asserted-by":"crossref","unstructured":"Maor MH. Radiotherapy for meningiomas. J Neurooncol. 1996;29:261-267.","DOI":"10.1007\/BF00165656"},{"key":"key\n\t\t\t\t20171013170945_","doi-asserted-by":"crossref","unstructured":"Miralbell R, Linggood RM, de la Monte S, Convery K, Munzenrider JE, Mirimanoff RO. The role of radiotherapy in the treatment of subtotally resected benign meningiomas. J Neurooncol. 1992;13:157-164.","DOI":"10.1002\/ijc.2910460504"},{"key":"key\n\t\t\t\t20171013170945_REF8","unstructured":"Stafford SL, Pollock BE, Foote RL, et al. Meningioma radiosurgery: tumor control, outcomes, and complications among 190 consecutive patients. Neurosurgery. 2001;49:1029-1038."},{"key":"key\n\t\t\t\t20171013170945_REF9","doi-asserted-by":"crossref","unstructured":"Taylor BW Jr, Marcus RB Jr, Friedman WA, Ballinger WE Jr, Million RR. The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 1988;15:299-304.","DOI":"10.1016\/S0360-3016(98)90008-6"},{"key":"key\n\t\t\t\t20171013170945_REF10","doi-asserted-by":"crossref","unstructured":"Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsend JJ. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993;15:75-77.","DOI":"10.1007\/BF01050266"},{"key":"key\n\t\t\t\t20171013170945_REF11","unstructured":"Grunberg SM, Rankin C, Townsend J, et al. Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. Proc Am Soc Clin Oncol. 2001;20:222."},{"key":"key\n\t\t\t\t20171013170945_REF12","doi-asserted-by":"crossref","unstructured":"Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004;62:1210-1212.","DOI":"10.1212\/01.WNL.0000118300.82017.F4"},{"key":"key\n\t\t\t\t20171013170945_","doi-asserted-by":"crossref","unstructured":"Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol. 2006;78:271-276.","DOI":"10.1002\/ijc.2910460504"},{"key":"key\n\t\t\t\t20171013170945_REF14","unstructured":"Cusimano MD. Hydroxyurea for treatment of meningioma. J Neurosurg. 1998;88:938-939."},{"key":"key\n\t\t\t\t20171013170945_REF15","doi-asserted-by":"crossref","unstructured":"Kaba SE, DeMonte F, Bruner JM, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997;40:271-275.","DOI":"10.1097\/00006123-199702000-00007"},{"key":"key\n\t\t\t\t20171013170945_REF16","doi-asserted-by":"crossref","unstructured":"Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg. 2002;97:341-346.","DOI":"10.3171\/jns.2002.97.2.0341"},{"key":"key\n\t\t\t\t20171013170945_REF17","doi-asserted-by":"crossref","unstructured":"Newton HB, Scott SR, Volpi C. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg. 2004;18:495-499.","DOI":"10.1080\/02688690400012392"},{"key":"key\n\t\t\t\t20171013170945_REF18","doi-asserted-by":"crossref","unstructured":"Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg. 1997;86:840-844.","DOI":"10.3171\/jns.1997.86.5.0840"},{"key":"key\n\t\t\t\t20171013170945_REF19","doi-asserted-by":"crossref","unstructured":"Black PM, Carroll R, Glowacka D, Riley K, Dashner K. Platelet-derived growth factor expression and stimulation in human meningiomas. J Neurosurg. 1994;81:388-393.","DOI":"10.3171\/jns.1994.81.3.0388"},{"key":"key\n\t\t\t\t20171013170945_","doi-asserted-by":"crossref","unstructured":"Guha A, Dashner K, Black PM, Wagner JA, Stiles CD. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer. 1995;60:168-173.","DOI":"10.1002\/ijc.2910460504"},{"key":"key\n\t\t\t\t20171013170945_","doi-asserted-by":"crossref","unstructured":"Hermanson M, Funa K, Hartman M, et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 1992;52:3213-3219.","DOI":"10.1002\/ijc.2910460504"},{"key":"key\n\t\t\t\t20171013170945_REF22","doi-asserted-by":"crossref","unstructured":"Johnson MD, Woodard A, Kim P, Frexes-Steed M. Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells. J Neurosurg. 2001;94:293-300.","DOI":"10.3171\/jns.2001.94.2.0293"},{"key":"key\n\t\t\t\t20171013170945_REF23","doi-asserted-by":"crossref","unstructured":"Kirsch M, Wilson JC, Black P. Platelet-derived growth factor in human brain tumors. J Neurooncol. 1997;35:289-301.","DOI":"10.1023\/A:1005872718547"},{"key":"key\n\t\t\t\t20171013170945_","doi-asserted-by":"crossref","unstructured":"Maxwell M, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniades HN. Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products. Int J Cancer. 1990;46:16-21.","DOI":"10.1002\/ijc.2910460504"},{"key":"key\n\t\t\t\t20171013170945_REF25","doi-asserted-by":"crossref","unstructured":"Maxwell M, Naber SP, Wolfe HJ, et al. Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J Clin Invest. 1990;86:131-140.","DOI":"10.1172\/JCI114675"},{"key":"key\n\t\t\t\t20171013170945_","doi-asserted-by":"crossref","unstructured":"Nagashima G, Asai J, Suzuki R, Fujimoto T. Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression. Brain Tumor Pathol. 2001;18:1-5.","DOI":"10.1002\/ijc.2910460504"},{"key":"key\n\t\t\t\t20171013170945_","doi-asserted-by":"crossref","unstructured":"Nister M, Claesson-Welsh L, Eriksson A, Heldin CH, Westermark B. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J Biol Chem. 1991;266:16755-16763.","DOI":"10.1002\/ijc.2910460504"},{"key":"key\n\t\t\t\t20171013170945_REF28","doi-asserted-by":"crossref","unstructured":"Todo T, Adams EF, Fahlbusch R, Dingermann T, Werner H. Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg. 1996;84:852-859.","DOI":"10.3171\/jns.1996.84.5.0852"},{"key":"key\n\t\t\t\t20171013170945_","doi-asserted-by":"crossref","unstructured":"Wang JL, Nister M, Hermansson M, Westermark B, Ponten J. Expression of PDGF beta-receptors in human meningioma cells. Int J Cancer. 1990;46:772-778.","DOI":"10.1002\/ijc.2910460504"},{"key":"key\n\t\t\t\t20171013170945_REF30","doi-asserted-by":"crossref","unstructured":"Yang SY, Xu GM. Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas. J Clin Neurosci. 2001;8(suppl 1):49-53.","DOI":"10.1054\/jocn.2001.0877"},{"key":"key\n\t\t\t\t20171013170945_REF31","unstructured":"Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100-104."},{"key":"key\n\t\t\t\t20171013170945_REF32","doi-asserted-by":"crossref","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.","DOI":"10.1056\/NEJM200104053441402"},{"key":"key\n\t\t\t\t20171013170945_REF33","doi-asserted-by":"crossref","unstructured":"Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.","DOI":"10.1056\/NEJM200104053441401"},{"key":"key\n\t\t\t\t20171013170945_REF34","doi-asserted-by":"crossref","unstructured":"Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.","DOI":"10.1056\/NEJMoa020461"},{"key":"key\n\t\t\t\t20171013170945_REF35","doi-asserted-by":"crossref","unstructured":"Wen PY, Yung WK, Lamborn KR, et al. Phase I\/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006;12:4899-4907.","DOI":"10.1158\/1078-0432.CCR-06-0773"},{"key":"key\n\t\t\t\t20171013170945_REF36","doi-asserted-by":"crossref","unstructured":"Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.","DOI":"10.1200\/JCO.1990.8.7.1277"},{"key":"key\n\t\t\t\t20171013170945_REF37","doi-asserted-by":"crossref","unstructured":"Parise RA, Ramanathan RK, Hayes MJ, Egorin MJ. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;791:39-44.","DOI":"10.1016\/S1570-0232(03)00206-X"},{"key":"key\n\t\t\t\t20171013170945_REF38","doi-asserted-by":"crossref","unstructured":"Pollack IF, Jakacki RI, Blaney SM, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro-Oncology. 2007;9:145-160.","DOI":"10.1215\/15228517-2006-031"},{"key":"key\n\t\t\t\t20171013170945_REF39","doi-asserted-by":"crossref","unstructured":"Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44:879-894.","DOI":"10.2165\/00003088-200544090-00001"},{"key":"key\n\t\t\t\t20171013170945_REF40","doi-asserted-by":"crossref","unstructured":"Widmer N, Decosterd LA, Csajka C, et al. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol. 2006;62:97-112.","DOI":"10.1111\/j.1365-2125.2006.02719.x"},{"key":"key\n\t\t\t\t20171013170945_REF41","doi-asserted-by":"crossref","unstructured":"Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496-3499.","DOI":"10.1182\/blood-2006-07-036012"},{"key":"key\n\t\t\t\t20171013170945_REF42","doi-asserted-by":"crossref","unstructured":"Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022-4028.","DOI":"10.1182\/blood-2007-10-116475"},{"key":"key\n\t\t\t\t20171013170945_REF43","doi-asserted-by":"crossref","unstructured":"Jain RK, Lahdenranta L, Fukumura D. Targeting platelet-derived growth factor signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model. PLoS Med. 2008;5(1):e24; doi:10.1371\/journal.pmed.0050024.","DOI":"10.1371\/journal.pmed.0050024"},{"key":"key\n\t\t\t\t20171013170945_REF44","doi-asserted-by":"crossref","unstructured":"Jain RK. Normalization of the tumor vasculature: an emerging concept in anti-angiogenic therapy. Science2005;307:58-62.","DOI":"10.1126\/science.1104819"},{"key":"key\n\t\t\t\t20171013170945_REF45","doi-asserted-by":"crossref","unstructured":"Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol. 2005;16:1702-1708.","DOI":"10.1093\/annonc\/mdi317"},{"key":"key\n\t\t\t\t20171013170945_REF46","doi-asserted-by":"crossref","unstructured":"Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005;23:9359-9368.","DOI":"10.1200\/JCO.2005.03.2185"},{"key":"key\n\t\t\t\t20171013170945_REF47","doi-asserted-by":"crossref","unstructured":"Norden AD, Drappatz J, Wen PY. Targeted drug therapy for meningiomas. Neurosurg Focus. 2007;23:E12.","DOI":"10.3171\/FOC-07\/10\/E12"},{"key":"key\n\t\t\t\t20171013170945_REF48","doi-asserted-by":"crossref","unstructured":"Andersson U, Guo D, Malmer B, et al. Epidermal growth factor receptor family (EGFR, ErbB2\u20134) in gliomas and meningiomas. Acta Neuropathol2004;108:135-142.","DOI":"10.1007\/s00401-004-0875-6"},{"key":"key\n\t\t\t\t20171013170945_REF49","doi-asserted-by":"crossref","unstructured":"Carroll RS, Black PM, Zhang J, et al. Expression and activation of epidermal growth factor receptors in meningiomas. J Neurosurg. 1997;87:315-323.","DOI":"10.3171\/jns.1997.87.2.0315"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/11\/6\/853\/13065822\/15_NO08-00173_Wen_FF.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T17:10:18Z","timestamp":1507914618000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article\/11\/6\/853\/1454910\/Phase-II-study-of-imatinib-mesylate-for-recurrent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,1]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2009,12,1]]},"published-print":{"date-parts":[[2009,12,1]]}},"URL":"https:\/\/doi.org\/10.1215\/15228517-2009-010","relation":{},"ISSN":["1523-5866","1522-8517"],"issn-type":[{"value":"1523-5866","type":"electronic"},{"value":"1522-8517","type":"print"}],"subject":[],"published-other":{"date-parts":[[2009,12]]},"published":{"date-parts":[[2009,12,1]]}}}